In 2023, diabetes medications remained the leading drug category for eligible private insurance claims for the second consecutive year, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 15 million plan members in 2023, found the growing prevalence of diabetes, along with expanded heart failure treatment indications and […]
Canadian employers have taken important steps forward on a range of diversity, equity and inclusion matters. That work continues, particularly in the context of neurodiversity, which applies to an estimated 15 per cent to 20 per cent of the global population. Neurodiversity is a broad category that includes autism, attention-deficit hyperactivity disorder, dyslexia, Tourette’s syndrome, […]
With chronic conditions growing in prevalence among plan members, plan sponsors have their work cut out for them in designing benefits plans that provide adequate health support and employee satisfaction while also being cost effective, said Marie-Hélène Dugal, manager of pharmacy benefit strategy for Medavie Blue Cross, during Benefits Canada’s 2023 Face to Face Drug […]
With hybrid and remote working arrangements becoming increasingly common, employers can take an inclusive approach to help employees with attention deficit hyperactivity disorder feel more engaged and productive, says Dr. Marie-Hélène Geoffroy, a family medicine physician at the Cleveland Clinic Canada. “ADHD needs structure and remote working requires individuals to manage their own schedule and tasks, […]
Three main drug categories — diabetes, asthma and stimulants for attention deficit hyperactivity disorder — accounted for rising drug claims in 2022, according to Lavina Viegas, Telus Health’s director of client account management, speaking during Benefits Canada‘s 2023 Benefits & Pension Summit in June. Referring to Telus Health’s 2023 drug plan trends report, she said […]
Specialty drugs are accounting for a slightly smaller portion of the total eligible amount for all drug claims, declining from 33.6 per cent in 2021 to 33.1 per cent in 2022, according to Telus Health’s annual drug trends report. The report, based on claims data from more than 4.6 million plan members in 2022, found the […]
As the coronavirus pandemic enters its fourth year, it’s perhaps unsurprising that the health crisis has taken its toll on employee mental health. Scotiabank saw a notable rise in claims for mental-health drugs in 2022, says Ayman Alvi, the bank’s vice-president of global pension and benefits, noting the increased use of these medications aligns with […]
Attention deficit hyperactivity disorder is commonly misunderstood and can reduce the ability of a person to function while impacting their quality of life, said Anjila Arora, director of pharmaceutical benefits at Sun Life Financial Inc., during a session at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December. Although ADHD […]